Jiangxi Bio has capitalized on the talent‑attraction outcomes of the “Ganhai Hui Zhi” initiative, driving international collaborative innovation in antitoxin products.

 

Jiangxi Bio’s Ganhai Huizhi Antitoxin Product Symposium and Cooperation Exchange Meeting

 

To thoroughly implement Jiangxi Province’s “Ganhai Huizhi” initiative for attracting overseas talent and fostering international scientific and technological exchanges, and in response to the provincial and municipal science and technology associations’ call to leverage the Hai Zhi Program workstations in “pooling talent, attracting expertise, and driving innovation,” while aligning closely with the province’s needs for upgrading its biopharmaceutical industry chain, the Hai Zhi Program workstation of Jiangxi Institute of Biological Products Co., Ltd. recently successfully hosted the “Ganhai Huizhi” Symposium and Cooperation Forum on Antitoxin Products in Nigeria. Through pragmatic measures, the event built a bridge for international scientific and technological collaboration, demonstrated the tangible effectiveness of the Hai Zhi workstations in attracting both talent and expertise, and injected international momentum into the high-quality development of the biopharmaceutical sector.

 

As a key platform for attracting talent and expertise under the guidance of the provincial and municipal science and technology associations, the Jiangxi Bio Hai Zhi Program Workstation has remained committed to its original mission of “pooling global wisdom, breaking through core technologies, and serving industrial development.” Leveraging high‑end innovation platforms such as the provincial enterprise technology center, the provincial R&D center for biological immune antibody drugs, and the postdoctoral innovation practice base, it has assembled an international, highly professional team of scientists and engineers led by doctors and masters. The workstation has long been deeply engaged in critical areas including antibody drug R&D, immunoserum production, international drug registration, and optimization of biomanufacturing processes, striving to establish a world‑leading hub for the serum industry and providing robust support for the independent and controllable development of China’s antibody drug sector.

 

 

This exchange event represents an important step in the workstation’s implementation of the “Ganhai Huizhi” talent‑attraction policy and its efforts to deepen international scientific and technological cooperation. It also serves as a vivid illustration of the provincial and municipal science and technology associations’ “going global and bringing in” approach to overseas‑talent initiatives. Centered on “technological breakthroughs, process optimization, international registration, and mutually beneficial market outcomes,” the event focused on the R&D of key new products—including enhanced‑efficacy tetanus antitoxin and antiviral immunoglobulin—while forging a bridge for in‑depth collaboration among international academia, industry, and research institutions. Notably, renowned Nigerian biopharmaceutical expert AUGUSTINE EMEKA UGBALA was invited to attend, engaging in intensive discussions with the company’s core teams from R&D, manufacturing, quality assurance, and international business. Through coordinated efforts and aligned priorities, participants jointly explored new pathways for high‑quality development in the antitoxin sector and sketched out a fresh blueprint for international cooperation.

 

 

During the exchange, the scientific and technical core team from the company’s Hai Zhi Program workstation provided Ugbala with a detailed update on the major project progress related to the urgently needed Class I innovative drug—respiratory syncytial virus (RSV) antibody serum—highlighting the antigen platform, engineering‑based preparation, and other core technological pathways, as well as the achievements made in overcoming key technical challenges. The two sides engaged in an in-depth discussion on critical scientific issues, including breakthroughs in delivery systems and the optimization of immobilized enzyme‑cleavage processes. Drawing on international cutting‑edge experience, Ugbala offered targeted guidance and recommendations for refining the project’s technology, enhancing process stability, and advancing international regulatory submissions. Meanwhile, focusing on core priorities such as improving antitoxin product quality and optimizing manufacturing processes, Ugbala delivered a specialized presentation, providing the company with an international perspective and expert solutions to support its R&D efforts. Participants then engaged in lively discussions around the challenges of ongoing product development and the requirements for international registration, sparking innovative ideas and addressing bottlenecks in the company’s growth.

 

 

During the exchange meeting, Ugbara also conducted on-site visits to the company’s R&D laboratory, pilot‑scale platform, and production facilities, engaging in one‑on‑one technical discussions. He put forward specific recommendations for improving processes related to manufacturing, quality control, and technology transfer, thereby helping the enterprise enhance its end‑to‑end R&D and production capabilities. The two sides reached several pragmatic agreements on collaborative initiatives, including joint R&D, technology licensing, international market access, and overseas regulatory submissions. They particularly discussed launching intellectual property protection and anti‑counterfeiting efforts for the company’s products in Nigeria, working together to safeguard the brand’s reputation and ensure local medication safety, thus laying a solid foundation for future long‑term international cooperation.

 

The successful organization of this event represents both a concrete step taken by the Jiangxi Bio‑Hai Zhi Workstation in implementing the provincial and municipal science and technology associations’ directives on Hai Zhi initiatives, and a concentrated demonstration of the workstation’s achievements in attracting talent and expertise as well as fostering international cooperation. It has effectively facilitated the precise alignment of high‑level overseas intellectual resources with the innovation needs of enterprises, injecting fresh momentum into technological innovation and the internationalization of the biopharmaceutical industry.

 

Going forward, the Jiangxi Bio‑Hai Zhi Program Workstation will, under the guidance of the provincial and municipal science and technology associations, continue to deepen its efforts in attracting talent and expertise through the “Gan Hai Hui Zhi” initiative. It will further broaden channels for international scientific and technological cooperation, pool global innovation resources, strengthen research on critical core technologies, accelerate the localization and commercialization of cutting‑edge international technologies, and drive the iterative development of antitoxin product technologies as well as the R&D of new products, thereby continuously enhancing the international competitiveness of its offerings. At the same time, the workstation will fully leverage its role as a bridge and liaison, establishing an international platform for exchange and collaboration in the biomedical sector in Ji’an. Together, it will advance the overseas registration of antivenom serums and their entry into the Nigerian market, helping to reinforce, supplement, and extend Jiangxi’s biomedical industry chain. In doing so, it will make a greater contribution to the high‑quality development of the province’s biomedical industry, to building Jiangxi into a science‑and‑technology powerhouse, and to the high‑quality advancement of provincial and municipal Hai Zhi initiatives.